Literature DB >> 30989576

Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis.

D Kyziridis1, A Kalakonas1, K Zarambouka2, C Hristakis1, Antonios-Apostolos K Tentes3.   

Abstract

Entities:  

Year:  2020        PMID： 30989576     DOI： 10.1007/s12029-019-00236-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  24 in total

1.  Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study.

Authors:  Sanket Mehta; Lilian Schwarz; John Spiliotis; Mao-Chih Hsieh; Eduardo H Akaishi; Diane Goere; Paul H Sugarbaker; Dario Baratti; François Quenet; David L Bartlett; Laurent Villeneuve; Vahan Kepenekian
Journal:  Eur J Surg Oncol       Date:  2018-05-28       Impact factor: 4.424

2.  Bile duct thrombi in hepatocellular carcinoma: is aggressive surgery worthwhile?

Authors:  Ashwin Rammohan; Jeswanth Sathyanesan; Kamalakannan Rajendran; Anbalagan Pitchaimuthu; Senthil K Perumal; Kesavan Balaraman; Ravi Ramasamy; Ravichandran Palaniappan; Manoharan Govindan
Journal:  HPB (Oxford)       Date:  2015-01-09       Impact factor: 3.647

3.  [Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient].

Authors:  C Braune; J Fangmann; G F Scheumann; J Klempnauer
Journal:  Zentralbl Chir       Date:  2001-04       Impact factor: 0.942

4.  Aggressive surgical management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report.

Authors:  Maciej Wojcicki; Jerzy Lubikowski; Mariola Post; Tomasz Chmurowicz; Anna Wiechowska-Kozlowska; Marek Krawczyk
Journal:  JOP       Date:  2012-09-10

5.  Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  P H Sugarbaker; K A Jablonski
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

Review 6.  A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma.

Authors:  Michael N Mavros; Skye C Mayo; Omar Hyder; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-09-13       Impact factor: 6.113

7.  Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.

Authors:  Yehuda Z Patt; Manal M Hassan; Richard D Lozano; Thomas D Brown; J Nicolas Vauthey; Steven A Curley; Lee M Ellis
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544

8.  Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Armando Sardi; William Jimenez; Carol Nieroda; Michelle Sittig; Suven Shankar; Vadim Gushchin
Journal:  Ann Surg Oncol       Date:  2013-11-26       Impact factor: 5.344

Review 9.  Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments.

Authors:  Woubet Tefera Kassahun
Journal:  World J Surg Oncol       Date:  2016-05-23       Impact factor: 2.754

Review 10.  Fibrolamellar hepatocellular carcinoma: current clinical perspectives.

Authors:  Kelly J Lafaro; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2015-10-09
View more
  1 in total

Review 1.  A Multidisciplinary Approach to the Management of Fibrolamellar Carcinoma: Current Perspectives and Future Prospects.

Authors:  Georgios Polychronidis; Anastasia Murtha-Lemekhova; Juri Fuchs; Evdokia Karathanasi; Katrin Hoffmann
Journal:  Onco Targets Ther       Date:  2022-10-03       Impact factor: 4.345
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.